» Articles » PMID: 30650088

Adjunct Phage Treatment Enhances the Effectiveness of Low Antibiotic Concentration Against Staphylococcus Aureus Biofilms in Vitro

Overview
Journal PLoS One
Date 2019 Jan 17
PMID 30650088
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Phage therapy is drawing more interest as antibiotic resistance becomes an ever more serious threat to public health. Bacterial biofilms represent a major obstacle in the fight against bacterial infections as they are inherently refractory to many types of antibiotics. Treating biofilms with phage has shown promise in a handful of experimental and case studies. However, quantification of the effect of phage combined with antibiotics is needed to pave the way for larger clinical trials. Here we explore the effect of using phage in combination with a total of nine antibiotics, applied simultaneously or as a pretreatment before antibiotics are applied to in vitro biofilms of Staphylococcus aureus. Most antibiotics alone were ineffective at low concentration (2×MIC), but the addition of phage to treatment regimens led to substantial improvements in efficacy. At high concentration (10×MIC), antibiotics alone were effective, and in most cases the addition of phage to treatment regimens did not improve efficacy. Using phage with rifampin was also very effective at reducing the outgrowth of resistant strains during the course of treatment.

Citing Articles

A theoretical exploration of protocols for treating prosthetic joint infections with combinations of antibiotics and bacteriophage.

Levin B, Gil-Gil T, Berryhill B, Woodworth M bioRxiv. 2025; .

PMID: 39990355 PMC: 11844561. DOI: 10.1101/2025.02.16.638499.


Piezoelectric biosensor with dissipation monitoring enables the analysis of bacterial lytic agent activity.

Oborilova R, Kucerova E, Botka T, Vaisocherova-Lisalova H, Skladal P, Farka Z Sci Rep. 2025; 15(1):3419.

PMID: 39870739 PMC: 11772602. DOI: 10.1038/s41598-024-85064-x.


Response of to combination of virulent bacteriophage vB_SauM-515A1 and linezolid.

Abdraimova N, Shitikov E, Bespiatykh D, Gorodnichev R, Klimina K, Veselovsky V Front Microbiol. 2025; 15:1519312.

PMID: 39760077 PMC: 11695419. DOI: 10.3389/fmicb.2024.1519312.


Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections.

Palma M, Qi B Infect Dis Rep. 2024; 16(6):1127-1181.

PMID: 39728014 PMC: 11675988. DOI: 10.3390/idr16060092.


It takes two to tango: Preserving daptomycin efficacy against daptomycin-resistant MRSA using daptomycin-phage co-therapy.

Madison C, Steinert A, Luedeke C, Hajjafar N, Srivastava P, Berti A Microbiol Spectr. 2024; :e0067924.

PMID: 39470283 PMC: 11619598. DOI: 10.1128/spectrum.00679-24.


References
1.
Ferreira F, Souza R, Bonelli R, Americo M, Fracalanzza S, Figueiredo A . Comparison of in vitro and in vivo systems to study ica-independent Staphylococcus aureus biofilms. J Microbiol Methods. 2012; 88(3):393-8. DOI: 10.1016/j.mimet.2012.01.007. View

2.
Khan W, Bernier S, Kuchma S, Hammond J, Hasan F, OToole G . Aminoglycoside resistance of Pseudomonas aeruginosa biofilms modulated by extracellular polysaccharide. Int Microbiol. 2011; 13(4):207-12. PMC: 3721063. DOI: 10.2436/20.1501.01.127. View

3.
Abedon S . Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages. Pharmaceuticals (Basel). 2015; 8(3):525-58. PMC: 4588182. DOI: 10.3390/ph8030525. View

4.
Waters E, Neill D, Kaman B, Sahota J, Clokie M, Winstanley C . Phage therapy is highly effective against chronic lung infections with . Thorax. 2017; 72(7):666-667. PMC: 5520275. DOI: 10.1136/thoraxjnl-2016-209265. View

5.
Debarbieux L, Pirnay J, Verbeken G, De Vos D, Merabishvili M, Huys I . A bacteriophage journey at the European Medicines Agency. FEMS Microbiol Lett. 2015; 363(2):fnv225. PMC: 5812529. DOI: 10.1093/femsle/fnv225. View